

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FRESENIUS KABI USA, LLC,
Petitioner,

v.

NOVO NORDISK A/S,
Patent Owner.

Case IPR2022-00657
Patent 8,114,833

PATENT OWNER'S UPDATED EXHIBIT LIST

EXHIBIT LIST

Exhibit No.	Description
2001	Declaration of Ryan P. Johnson in Support of Patent Owner's Motion for Admission <i>Pro Hac Vice</i> of Ryan P. Johnson.
2002	Declaration of Laura T. Moran in Support of Patent Owner's Motion for Admission <i>Pro Hac Vice</i> of Laura T. Moran.
2003	March 13, 2012 Submission From Patent Owner to FDA Requesting Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") Listing of the '833 patent
2004	Excerpt from the 2013 Annual Edition of the Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"), Victoza [®] Listing
2005	European Patent 1,687,019 B1
2006	Fresenius Kabi Deutschland GmbH Notice of Opposition Against European Patent 1,687,019 B1
2007	Confidential Settlement Agreement (Business Confidential Information)
2008	Confidential Settlement Agreement (Business Confidential Information)

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6 and 42.105, I hereby certify that the foregoing document was served on **September 7, 2022**, by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Linnea Cipriano (Reg. No. 67,729)
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
Tel: (212) 813 8800
lqipriano@goodwinlaw.com

Daryl Wiesen (pro hac vice
application to be filed)
GOODWIN PROCTER LLP
100 Northern Ave.
Boston, MA 02210
Tel: (617) 570 1000
dwiesen@goodwinlaw.com

Date: September 7, 2022

Respectfully submitted,

/Jeffrey J. Oelke/
Jeffrey J. Oelke (Reg. No. 37,409)

Counsel for Novo Nordisk A/S